Literature DB >> 16763470

Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model.

Sanjay Gupta1, Satoshi Kobayashi, Sith Phongkitkarun, Lyle D Broemeling, Zuxing Kan.   

Abstract

OBJECTIVES: Transcatheter arterial embolization (TAE) is used for the treatment of patients with malignant liver tumors. However, the proangiogenesis effect of TAE-associated hypoxia has not been adequately studied. The goal of this study was to determine angiogenic activity in tumors subjected to TAE by evaluating the tumor microvessel density (MVD).
MATERIALS AND METHODS: Mammary cancer 13762 NF tumor cells were inoculated into the livers of male Sprague-Dawley rats. TAE was performed 12-14 days after tumor inoculation. Rats were divided into 4 groups on the basis of treatment type. Control group animals (n = 16) were subjected to sham TAE without polyvinyl alcohol (PVA) particles. Animals in the other 3 groups were subjected to TAE with 1 (n = 11), 2 (n = 8), or 3 (n = 10) mg of PVA particles. Rats were killed 3-6 hours or 2 or 3 days after embolization, and the liver tumor tissues were dissected and frozen in liquid nitrogen. Tumor tissue slides were prepared, stained with CD-31, and evaluated for MVD. Blood samples collected just before sacrificing the animals were used to measure serum vascular endothelial growth factor (VEGF) levels.
RESULTS: Tumors treated with TAE showed varying degrees of central necrosis with residual viable tumor cells in the periphery. Tumor MVD in animals treated with TAE was significantly higher than that in the control group (23.6 versus 17.5; P = 0.001). Although the MVD in animals treated with TAE using 1 mg of PVA was higher than that in the control group, this difference was not statistically significant. TAE using 2 mg of PVA resulted in a significant increase in tumor MVD (25.9 versus 17.5; P = 0.007). Use of 3 mg of PVA did not result in any further increase in MVD. There was a significant increase in tumor MVD in the animals killed 2 or 3 days after TAE compared with the control group (24.5 versus 17.5; P = 0.002). The animals treated with TAE showed a statistically significant increase in VEGF levels compared with the control group.
CONCLUSIONS: TAE of hepatic tumors results in the stimulation of angiogenesis in the residual viable tumor, which could have an adverse effect on the therapeutic efficacy of TAE.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16763470     DOI: 10.1097/01.rli.0000209663.00629.8a

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  16 in total

1.  A preclinical study on the combination therapy of everolimus and transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Ariel Km Chow; Thomas Cc Yau; Lui Ng; Andrew Cy Chu; Wai-Lun Law; Ronnie Tp Poon; Roberta Wc Pang
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

2.  Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma.

Authors:  Weiguang Xu; Jung-Hee Kwon; Young Ho Moon; Young Bae Kim; Yun Suk Yu; Namgyu Lee; Kwan Yong Choi; Yun Soo Kim; Yong Keun Park; Bong Wan Kim; Hee Jung Wang
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-23       Impact factor: 4.553

Review 3.  Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization.

Authors:  Osamu Matsui
Journal:  Clin Drug Investig       Date:  2012-08-08       Impact factor: 2.859

4.  Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.

Authors:  Roderich E Schwarz; Ghassan K Abou-Alfa; Jeffrey F Geschwind; Sunil Krishnan; Riad Salem; Alan P Venook
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

5.  The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma.

Authors:  Jun Kajihara; Yoshito Tomimaru; Hidetoshi Eguchi; Daisaku Yamada; Hiroshi Wada; Akira Tomokuni; Tadafumi Asaoka; Koichi Kawamoto; Shigeru Marubashi; Hiroaki Nagano; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

6.  Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma.

Authors:  Masayasu Jo; Taichiro Nishikawa; Tomoki Nakajima; Yoshihisa Okada; Kanji Yamaguchi; Hironori Mitsuyoshi; Kohichiroh Yasui; Masahito Minami; Masaki Iwai; Keizo Kagawa; Yoshito Itoh; Toshikazu Yoshikawa
Journal:  J Gastroenterol       Date:  2011-03-31       Impact factor: 7.527

7.  Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre.

Authors:  Agneta Norén; Jozef Urdzik; Frans Duraj; Charlotte Ebeling Barbier; Britt-Mari Karlson; Ulf Haglund
Journal:  HPB (Oxford)       Date:  2010-09-02       Impact factor: 3.647

Review 8.  Treatment of Liver Cancer.

Authors:  Chun-Yu Liu; Kuen-Feng Chen; Pei-Jer Chen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-17       Impact factor: 6.915

9.  Addition of transcatheter arterial chemoembolization decreased local recurrence but had no survival benefit to percutaneous ethanol injection therapy for patients with small hepatocellular carcinoma: A multicenter randomized control study.

Authors:  Akira Mizuki; Masayuki Tatemichi; Nobuhiro Tsukada; Ryousuke Nagamatsu; Mitsuhiko Kawaguchi; Tatsuya Itoshima; Shigeki Maruyama; Atsuhiko Satou; Yasuhisa Imari; Toshiharu Kawatoko; Junya Shimono; Hiroshi Nagata
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

10.  Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation.

Authors:  Aymeric Guibal; Thibaud Lefort; Laurence Chardon; Noura Benslama; Sébastien Mulé; Franck Pilleul; Catherine Lombard-Bohas; Lori Bridal; Jean Alain Chayvialle; Olivier Lucidarme; Alban Denys; Thomas Walter
Journal:  Eur Radiol       Date:  2012-09-22       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.